Mallinckrodt (MNK) Affirms Enrollment of First Patient in H.P. Acthar Gel Phase 4 as SLE Treatment
Tweet Send to a Friend
Mallinckrodt plc (NYSE: MNK) confirmed enrollment of the first patients in the company's Phase 4 clinical study assessing the efficacy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
